We help leading pharmaceutical and biotech companies navigate and resolve contentious issues arising out of their life sciences contracts, especially those involving highly technical, IP-rich subject matter.

Our team has in-depth knowledge of the drug development life cycle from bench-scale production through to trial phases, regulatory approval, manufacture scale-up and commercialisation. This informed expertise means we are able to resolve a wide spectrum of disputes such as those relating to licensing IP and know-how, technical/quality agreements, research collaboration contracts, API manufacturing, development services, supply and distribution.

We also advise on product liability and misuse of confidential information matters related to medicinal drugs and medical devices.

Our clients trust us to assess and manage complex disputes through to resolution on a spread of issues including breach of contract, wrongful termination, royalty rate assessments, trial phases, GMP and regulatory compliance, product liability and misuse of confidential information. Where needed, we bring in expertise from our specialist life sciences regulatory, patent litigation and commercial contracts teams.

If unavoidable, we vigorously deploy our strong experience in litigation, arbitration and other forms of ADR such as mediation, expert determination and judicial review to protect our clients’ interests and enforce their rights.

Key contact

Mark Brown

Contact

Experience

Licence fees and royalty rate dispute of a pharma product: Representing a pharma company in relation to a claim for royalties under a collaboration agreement for the development of a monoclonal antibody blockbuster drug.

Wrongful termination and breaches of pharma product manufacture and supply contracts: Representing a pharma company in relation to the contested termination of manufacture and supply contracts of a licensed active pharmaceutical ingredient.

Breaches of technical quality contracts and regulatory compliance: Representing a pharma company in relation to claims against CMO for breaches of technical quality agreement, GMP guidelines and CAPAs concerning OOS API batches.

Breach of reasonable endeavours obligations under licence agreement: Advising a pharma company in a claim relating to breaches of a licence, development and commercialisation agreement for failure to comply with “reasonable endeavours” obligations to promote and sell a peptide drug.

Master Services Agreement for human drug trials: Advising a biotech client in relation to breaches of work orders under a master services agreement for the conduct of clinical trials.

Misuse of confidential information: Representing a pharma company in relation to allegations of misuse of confidential information relating to the formula of an active pharmaceutical ingredient.

Latest articles

What others say

“Bristows is a very good firm, particularly in coordinating multi-jurisdictional litigation. They have a good network of colleagues across Europe.”

Chambers and Partners Europe 2024

“The team at Bristows can always be relied on to provide balanced, pragmatic and business-savvy legal advice and solutions. We received strong support from partners and associates across a range of different business needs.”

Chambers and Partners 2024

“They are really great, client-centric, and very knowledgeable about the industry. The Bristows team comes up with pragmatic solutions, and adds a personal touch to advice. They have a solid team across the board. I do not see them as just there to make a profit. They are efficient and true partners.”

Chambers and Partners Europe 2024

“They have a clear understanding of what our business wants to achieve and that underpins all their advice. They know when to involve the business stakeholders and are able to tailor their approach to that audience and suggest solutions that take key business drivers into account.”

Chambers and Partners 2024

“Bristows has a comprehensive IT practice with powerful resources for major commercial transactions and complex litigation. It advises many of the world’s leading technology companies, and also sophisticated blue-chip buyers of IT services. It is especially adept at providing counsel on the most current and cutting-edge issues in the technology space. Bristows houses experienced advisers on digital advertising and cloud computing matters.”

Chambers and Partners 2024

“Notable experience in commercial disputes involving the technology, life sciences and consumer products sectors.”

Legal 500 2024

“One of the UK’s leading life sciences practices. Across the firm, there is tremendous strength in depth. Great understanding of the market through acting for a wide range of clients.”

Legal 500 2024

“A ‘truly exceptional’ [Life sciences] practice which assists clients with the full gamut of commercial, regulatory and IP-related issues.”

Legal 500 2024

“The Bristows Life Science team is truly exceptional and delivers high quality legal work thanks to their knowledge of the law, the industry and their technical skills.”

Legal 500 2024

“They are excellent, they have really good work and nice people there.”

Chambers and Partners 2023

“Their reputation is well deserved.”

Chambers and Partners 2023

“Bristows is known for its deep bench of high-calibre litigators with supreme expertise in contentious patent, trade mark, designs and copyright matters. The team is particularly sought after for biosimilars and telecommunications litigation, and is frequently instructed for standard-essential patent-related disputes. The Bristows IP team is also distinguished for its work on the commercialisation of IP at the vanguard of life sciences and technology, and is additionally recommended for its trade mark prosecution service.”

Chambers and Partners 2023

“Their advice is always practical, realistic and adaptable.”

Chambers and Partners 2023

“Bristows have an incredible depth and breadth of experience.”

Chambers and Partners 2023

“Bristows has a comprehensive IT practice with powerful resources for major commercial transactions and complex litigation. It advises many of the world’s leading technology companies, and also sophisticated blue-chip buyers of IT services. It is especially adept at providing counsel on the most current and cutting-edge issues in the technology space.”

Chambers and Partners 2023

Recent rankings and awards

Life Sciences - Band 1
Chambers and Partners UK 2021

Life Sciences: Transactional - Band 2
Chambers and Partners UK 2021

Life Sciences and Healthcare - Tier 1
Legal 500 2021

Commercial Litigation
Leaders League UK 2020